ABSTRACT
Description: PROCOMVAX (or COMVAX in the U.S.) is a vaccine consisting of antigenic components present in other previously marketed vaccines. PROCOMVAX contains polyribosylribitol phosphate from Haemophilus influenzae type b coupled to the outer membrane pro tein complex of Neisseria meningitidis and the major surface antigen of the hepatitis B virus produced by recombinant DNA technology in Saccharomyces cereυisiae. It is presented as a suspension for intramuscular injection. Each single-dose vial contains 7.5 µg of Hemophilus b polyribosylribitol phosphate (PRP) conjugated to 125 µg of the outer membrane protein complex of N. meningitidis and 5.0 µg of HBsAg as active substance, in a total volume of 0.5 ml.
